Envestnet Asset Management
ABCL icon

Envestnet Asset Management’s AbCellera Biologics ABCL Stock Holding History

Envestnet Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,716
Closed -$44.4K – 4823
2026
Q1 		$44.4K Buy
12,716
+715
+6% +$2.57K ﹤0.01% 4679
2025
Q4 		$41K Sell
12,001
-3,913
-25% -$17.5K ﹤0.01% 4423
2025
Q3 		$80K Sell
15,914
-2,396
-13% -$10.6K ﹤0.01% 4450
2025
Q2 		$62.8K Sell
18,310
-3,650
-17% -$9.09K ﹤0.01% 4380
2025
Q1 		$49K Buy
21,960
+3,532
+19% +$10.1K ﹤0.01% 4295
2024
Q4 		$54K Sell
18,428
-4,781
-21% -$13.3K ﹤0.01% 4260
2024
Q3 		$60.3K Buy
23,209
+8,210
+55% +$22.7K ﹤0.01% 4169
2024
Q2 		$44.4K Buy
14,999
+814
+6% +$3.08K ﹤0.01% 4113
2024
Q1 		$64.3K Buy
14,185
+1,021
+8% +$5.21K ﹤0.01% 4093
2023
Q4 		$75.2K Buy
13,164
+1,364
+12% +$6.32K ﹤0.01% 3965
2023
Q3 		$54.3K Buy
+11,800
New +$71.8K ﹤0.01% 3933

Other funds holding ABCL

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Envestnet Asset Management's ABCL Position: Q2 2026 in Review

Envestnet Asset Management sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 12,716 shares — an estimated $44.4K sold.

Envestnet Asset Management first reported a position in ABCL in Q3 2023 and held it in 11 quarters. The position peaked at $80K in Q3 2025. 62 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Envestnet Asset Management reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • Envestnet Asset Management sold 12,716 AbCellera Biologics shares in Q2 2026, an estimated $44.4K.
  • Envestnet Asset Management first reported a position in AbCellera Biologics in Q3 2023 and held it in 11 quarters.
  • Envestnet Asset Management's AbCellera Biologics position peaked at $80K in Q3 2025.
  • 62 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.